"The future of human health isn't waiting to be discovered. It's waiting to be implemented." — Futurist Jim Carroll
This is my Trends Scorecard series, where I go back into my own archive, dig up the predictions I actually made on stage years ago, and grade them honestly against where we've landed in 2026. No cherry-picking, no rewriting history. This time the industry is Healthcare & Pharma — an industry I've been speaking to since the early 2000s, from the World Pharma Innovation Congress in London to the World Healthcare Innovation & Technology Congress in Washington. Here's the scorecard.
The setup: I've been betting on this industry for twenty years.
And one thing I've learned is that healthcare doesn't have an opportunity problem. It has an implementation problem.
Here's the thing about healthcare. It moves at two speeds at once. The science screams forward at a furious pace, and the system crawls behind it, tangled in politics, inertia, and complexity. I've spent two decades telling rooms full of pharma executives, hospital CEOs, and benefits leaders the same core message: the future of medicine is a shift from "sick care" to actual "healthcare." Way back in 2006, I walked into a half-day session with a major pharmaceutical player and laid it out like this.
The big picture item is that we are in the midst of a fundamental, significant shift in healthcare philosophy and medical research: from a world in which we "react" to disease and illness after it has happened, to one in which we will be doing far more to "prevent" health care problems through highly personalized medicine. This is primarily coming about because of furious rates of discovery related to genomics. This more than anything will dominate the health care / pharmaceutical research / delivery agenda through the next years.
That was the thesis. Everything I said for the next twenty years built on it.
And it's not like I haven't spent a lot of time in the sector. I had Claude interrogate my blog and build a list of the groups I've spoken to over the years.It's quite the list!
- Pharmaceutical & Biotech — Pfizer, PhRMA, Genentech, Boehringer Ingelheim, Emergent Biosolutions, Icon PLC, NCPDP, National Pharmacy Forum, World Pharma Congress
- Hospitals & Health Systems— Greater Lansing HealthCare, Pennsylvania Hospital Association, Optima Health, Mercy Health,
- Medical Associations— American Medical Association, American Association of Orthopaedic Executives, American Health Care Association
- Medical Devices & Supplies) — Stryker, Phillips Medical Devices, Henry Schein
- Dental — Invisalign/Aligntech, Cain Watters, Ontario Dental Association, NADL
- Veterinary — Patterson Veterinary, North American Veterinary Community
- Health Plans, Benefits & Wellness— Magellan Health, Anthem Health, Highmark Health, NY Health Plans Association, Benefiq
- Congresses & Services — World Health Care Congress, World Health Care Innovation & Technology Congress, EY Healthcare Practice Summit, Practice Match
These are only the ones I've blogged about - gosh, there have been countless others!
So how did I do? Let's pull the receipts.
Prediction #1 — "From reactive to preventive" (2006) — Largely right
This was the foundational call: that genomics would drag the entire industry away from reactive treatment and toward personalized, preventative medicine. I made it in 2006, when the human genome was barely sequenced and most people had never heard the word "pharmacogenetics."
From a world in which we "react" to disease and illness after it has happened, to one in which we will be doing far more to "prevent" health care problems through highly personalized medicine. This is primarily coming about because of furious rates of discovery related to genomics. This more than anything will dominate the health care / pharmaceutical research / delivery agenda through the next years.
The grade: Largely right, and the direction was dead on. Personalized medicine and pharmacogenetics are now central to oncology, rare disease, and a growing list of conditions. Targeted therapies based on genetic markers are routine. The thesis was correct. The only reason this isn't a flat-out "nailed it" is timing : "this more than anything will dominate" the agenda was true for the science, slower for the system. But as a north star for where the whole industry was heading, this one holds up beautifully twenty years on.
Prediction #2 — "The genome cost curve falls off a cliff" (2012) — Nailed it
In 2012 I was speaking on corporate wellness and the consumerization of health, and I put a number on the table to show how fast the foundation of personalized medicine was getting cheap. I tracked the collapsing cost of sequencing a human genome.
It took $3 billion to sequence the first human genome. By 2009, that was down to $100,000. It's now under $10,000. And it is estimated by the end of 2012, $1,000.
The grade: Nailed it. The cost curve was real and it kept going. The $1,000 genome arrived right on schedule, and today sequencing has pushed toward the $100 to $200 range. I even joked in that talk that you'd soon buy a sequencing machine at Radio Shack. That was obviously a gag, but the underlying point was serious: when a cost curve falls this hard, it changes everything downstream. It did. Cheap sequencing is exactly what made the 2006 personalized-medicine thesis economically possible. This is the cleanest hit on the board.
Prediction #3 — "Your body becomes a data network" (2008) — Spot on
December 10, 2008. I was the closing keynote at the 4th World Healthcare Innovation & Technology Congress in Washington, and I did something I'd go on to do for years: I described a specific future day, January 15, 2020, and looked "back" at what had changed. One of my ten predictions was about device intelligence wrapping around our daily health.
By 2020, most of us found that our "personal area network" included much more than our MP3's, video players and other digital content: it included huge chunks of intelligence from our daily health interactions.
The grade: Spot on — and when I went back and graded my own 2008 keynote, I gave this one an A+. Go back and read the post: It's January 15, 2020 - it's an honest look back at every single prediction I made and how precise I was. Today? Look at your wrist. Heart rate, blood oxygen, ECG, sleep, steps, even glucose monitoring - the wearable became a continuous health sensor, and hundreds of millions of people now carry one. I'll be honest: I called this "low-hanging fruit" even back then. The trajectory of consumer tech invading the body was obvious. But obvious or not, it landed exactly as described.
Prediction #4 — "In-body sensors and predictive health dashboards" (2019) — Hit, and accelerating
By 2019 I was projecting into 2030, and I tightened the healthcare vision into one dense paragraph about how we'd re-architect the system around real-time prediction rather than reaction.
Genomics, mobile devices, embedded in-body health sensors and real time analytical predictive health care dashboards led us to a world in which we could predict the emergence of particular health care issues and risks on a real time basis. This resulted in a fundamental re-alignment of resources to manage any particular issue — 'disease management' became a world of 'disease action planning.'
The grade: Hit, and accelerating fast. Continuous glucose monitors went mainstream and over-the-counter. Implantable and ingestible sensors are in clinical use. AI-driven risk dashboards now flag sepsis, deterioration, and chronic-disease risk in real time inside hospital systems. The "disease action planning" framing — getting ahead of the condition instead of chasing it — is exactly the language health systems are adopting now. We aren't all the way to 2030 yet, but every piece of this is already on the table.
Prediction #5 — "We'll grow body parts in a lab" (2023) — Tracking - too early to grade
In 2023, as part of my BIG Future series, I went deep on regenerative medicine — the idea that we'd stop merely treating damaged tissue and start regrowing it.
We are quickly learning how to grow replacement tissues and organs in a lab, and how to stimulate the body's own repair mechanisms to deal with disease or accident-driven tissue damage. The acceleration of regenerative medicine is perhaps the most exciting, and most staggering of all trends in the world of healthcare science.
The grade: Tracking — too early to grade, and I want to be upfront about that. The science is genuinely staggering: lab-grown tissue, bioprinted structures, stem-cell therapies, and the first gene-edited and engineered-cell breakthroughs are real and accelerating. But "growing human organs for transplant" as a routine clinical reality? Not yet. We're in the lab and the early trials, not the operating room at scale. I stand behind the direction completely. I'm just not going to pretend the destination has arrived when it hasn't. Ask me again in 2030 — this is the one I most want to re-grade.
The one I got wrong
Back to that 2008 Washington keynote. My very first prediction — the headline one — was that by 2020 we'd have flipped the whole system upside down, from fixing people after they got sick to genuinely preventing illness in the first place.
By 2020, we had successfully transitioned the health care system from one which "fixed people after they were sick" to one of preventative, diagnostic medicine. Treating them for the conditions we know they were likely to develop.
The grade: I graded myself a C on this one when 2020 actually arrived. The system did not go upside down. The science of prevention raced ahead exactly as I predicted — cheap genomes, wearables, predictive analytics, all of it,. but the system itself stayed stubbornly "sick care."
Why? System inertia, brutal complexity, and a healthcare debate that's been swallowed whole by politics. And overall, that's the big problem with healthcare and medicine. There is all kinds of opportunity from science and technology, but people get in the way. I was right about the technology and wrong about the timeline, because I underestimated how hard institutions fight to stay the same. Not only that, but I did not anticipate that a significant portion of the population would descend into a world of whack-a-doodle-ding-dong-fruit-loop land.
The science was never the bottleneck. The system was. That's a mistake I've stopped making., now when I forecast a trend, I forecast the friction and idiocy that comes along with it.
What the scorecard tells us about what's next
Tally it up.
The science calls: genomics, the cost collapse, wearable sensors, predictive dashboards, regenerative medicine, were right , and most of them landed early. The system calls: the upside-down flip to true preventative care ran late, because institutions and politics move slower than discovery.
And that's the whole method right there: I track the trajectory of the science with confidence, and I respect the friction of the system with humility, but I fail on the implementation and politics. Get both right and you see the future clearly. Bet only on the technology and you'll be early. Bet only on the inertia and you'll miss the revolution entirely.
So where does healthcare go from here? That's a separate conversation, and a longer one than a scorecard can hold. I've mapped it out sector by sector in my current series, The Way Forward — the trends, the barriers, and the playbook for acting on them. If these receipts convinced you the method works, that's where you'll find where it's pointing next.
Next up in the Trends Scorecard series: Energy & Utilities — an industry where I made some very big, very specific bets on solar, storage, and the death of the centralized grid. Some of those receipts are going to be fun.